Caribou Biosciences

Caribou Biosciences is a clinical-stage CRISPR genomic editing biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its proprietary chRDNA technology to develop next-generation genomic editing allogeneic immune cell therapies. The company is developing a range of genomic editing, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of hematologic malignancies and solid tumors. These therapies target cell surface antigens and have previously demonstrated clinical proof-of-concept with autologous CAR-T cell therapies as well as other emerging targets.